

SHORT CURRICULUM VITAE

PERSONAL INFORMATION

Name and title	FIZAZI Karim, M.D., Ph.D.
Nationality	French
Address	Gustave Roussy 114 rue Edouard Vaillant, 94800 Villejuif, France
Mail	Karim.Fizazi@gustaveroussy.fr

HOSPITAL AND LABORATORY APPOINTMENTS

- Since September 2009: Full Professor, Gustave Roussy, University of Paris Sud
- 2005-2018: Appointed Head of the Department of Cancer Medicine, Institut Gustave Roussy (IGR), France.
- 2004-2010: Chairman of the Genito-urinary Oncology Group, IGR, France.
- 2001-2009: Assistant Professor in Medical Oncology, Department of Cancer Medicine, Institut Gustave Roussy (IGR), France.
- 1999-2001: Fellow and Visiting Assistant Professor, Genitourinary Medical Oncology Department, MD Anderson cancer Center, Houston, TX, USA.
- 1997-1999: Assistant Professor in Medical Oncology, Department of Cancer Medicine, Institut Gustave Roussy (IGR), France.
- 1995-1997: Appointed *Chef de clinique* (Fellow) Medical oncology, IGR
- 1991-1995: Appointed *Interne des hôpitaux de Paris* (Residency):
- 1994: *Diplôme d'Etudes Appliquées* : Postgraduate Diploma prior to PhD, Fundamental Bases of Oncogenesis, Pr Tursz' Laboratory, IGR

MEDICAL AND SCIENTIFIC QUALIFICATIONS

- 2006: Habilitation à diriger la recherche (HDR)
- 2003: Ph.D. (Molecular Oncology)
- 1997 : « Ancien Chef de Clinique » (Fellowship), Medical Oncology
- 1995 : MD (Medical Oncology)
- 1990: *Concours de l'Internat de Paris* (Competitive Examination) ranked 45 / 3000 candidates, Internal Medicine.
- October 1984 to June 1990: Medical school, University of Poitiers, France.

PUBLICATIONS

- Articles: 400 papers referenced in PubMed
- H-index: 80

LEADERSHIP SCIENTIFIC POSITIONS

- President of the Genito-Urinary Tumors Study Group (GETUG) since 2019.
- President of the evaluation committee of the Program for Hospital Clinical Research in Cancer – PHRC-k2019
- President of the French Study Group of Carcinomas of Unknown Primary (GEFCAPI) since 1998.
- Chief of the medical oncology subgroup of the French Genito-Urinary Tumors Study Group (GETUG) 2014-2019.
- Chairperson of national and global phase III clinical trials:
 - GETUG 12 (docetaxel in high-risk localized prostate cancer)
 - GETUG 13 (intensified chemotherapy in poor-risk NSGCT with unfavorable tumor marker decline)
 - GEFCAPI 04 (à la carte treatment of patients with carcinoma of an unknown primary site based on results from a molecular test)
 - Pivotal 103 denosumab phase III trial in CRPC: registration
 - ENTHUSE 33 (zibotentan plus docetaxel in CRPC)
 - COMET-1 (cabozantinib in CRPC)
 - LATITUDE (abiraterone in mCSPC): registration
 - PEACE-1 (abiraterone and local radiotherapy in mCSPC)
 - PEACE-2 (cabazitaxel and pelvic radiotherapy in high-risk localized prostate cancer)
 - ARAMIS (darolutamide in non-metastatic CRPC)
 - PEACE-4 (aspirin and statins in castrate-resistant prostate cancer)

DIPLOMAS

- 2006: Habilitation to conduct the research. University of Paris. “Outstanding and congratulations from the jury”. Predictive and prognostic factors of metastases in prostate cancer, germ cell tumors, and carcinoma of an unknown primary site.
- 2003: Ph.D. in Molecular Oncology, University of Paris. “Outstanding and congratulations from the jury”. Biology of bone metastases from prostate cancer.
- 1995: Thesis in Medicine, Lauréat of the Faculty (University of Paris)
- 1995: Inter-university diploma of breast disease (University of Paris)
- 1994: DEA "Postgraduate Diploma Fundamental Bases of Oncogenesis" (Paris).

- 1992: Masters in Biological and medical Sciences (Immunology (Pr Bach, Paris), Oncological Pharmacology (Pr Laugier, Paris))